自拟清肺定喘贴联合宣白承气汤治疗哮喘-慢性阻塞性肺疾病重叠综合征的效果及对肺功能、炎症因子的影响  

Effect of Self-Designed Qingfei Dingchuan Patch(自拟清肺定喘贴)Combined with Xuanbai Chengqi Decoction(宣白承气汤)in Treatment of Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome and Its Impact on Lung Function andInflammatory Factors

作　　者：倪嘉纳[1] 罗华[1] 陈旋[1] NI Jiana;LUO Hua;CHEN Xuan(Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200021,China)

机构地区：[1]上海中医药大学附属曙光医院,上海200021

出　　处：《辽宁中医杂志》2024年第11期112-115,共4页Liaoning Journal of Traditional Chinese Medicine

摘　　要：目的探讨自拟清肺定喘贴联合宣白承气汤治疗哮喘-慢性阻塞性肺疾病重叠综合征(asthma chronic obstructive pulmonary disease overlap syndrome,ACOS)的效果及对肺功能、炎症因子的影响。方法选择2021年10月—2023年3月该院收治的116例ACOS患者纳入研究,通过随机数表法分为观察组、对照组,各58例。对照组使用噻托溴铵、布地奈德福莫特罗治疗,观察组在对照组基础上,联合自拟清肺定喘贴、宣白承气汤治疗,两组均持续治疗8周。比较两组治疗后临床疗效,治疗前后哮喘症状评分(asthma control test,ACT)、慢性阻塞性肺疾病症状评分(chronic obstructive pulmonary disease assessment test,CAT)、第1秒用力呼气量(forced expiratory volume in the first second,FEV1)、FEV1/用力肺活量(FEV1/FVC)、呼气峰值流速(peak expiratory flow rate,PEFR)及血清肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-6(IL-6)、C反应蛋白(C-reactive protein,CRP)水平的变化及不良反应。结果观察组临床疗效总有效率为91.38%(53/58),高于对照组的75.86%(44/58),差异有统计学意义(P<0.05);观察组ACT评分为(20.61±1.95)分,明显高于对照组的(18.30±1.43)分,CAT评分为(15.02±2.31)分,明显低于对照组的(18.41±2.62)分,差异有统计学意义(P<0.05);且观察组FEV1、FEV1/FVC、PEFR分别为(2.20±0.27)L、(61.21±5.28)%、(3.88±0.36)L/s,均高于对照组的(1.93±0.21)L、(57.33±5.26)%、(3.67±0.41)L/s,差异有统计学意义(P<0.05);观察组血清TNF-α、IL-6、CRP分别为(31.70±5.42)ng/L、(22.05±3.29)ng/L、(9.75±1.60)mg/L,均低于对照组的(43.33±6.05)ng/L、(31.17±3.58)ng/L、(12.83±2.11)mg/L,差异有统计学意义(P<0.05);两组不良反应总发生率分别为10.34%(6/58)、8.62%(5/58),差异无统计学意义(P>0.05)。结论自拟清肺定喘贴联合宣白承气汤治疗ACOS患者疗效明显,能有效改善肺功能、降低炎症因子的表达,值得临床推广。Objective To study the effect of Self-Designed Qingfei Dingchuan Patch(自拟清肺定喘贴)combined with Xuanbai Chengqi Decoction(宣白承气汤)in the treatment of asthma chronic obstructive pulmonary disease overlap syndrome(ACOS)and its impact on lung function and inflammatory factors.Methods A total of 116 patients with ACOS admitted to the hospital from October 2021 to March 2023 were included in the study,and they were divided into observation group and control group by random number table method,with 58 patients in each group.On the basis of conventional treatment,the control group was treated with tiotropium bromide and budesonide formoterol.The observation group was combined with Self-Designed Qingfei Dingchuan Patch and Xuanbai Chengqi Decoction.Both groups were treated for 8 weeks.The clinical efficacy of the two groups after treatment was compared,and the changes of the asthma control test(ACT),chronic obstructive pulmonary disease assessment test(CAT),forced expiratory volume in the first second(FEV1),FEV1/forced vital capacity(FEV1/FVC),peak expiratory flow rate(PEFR),serum tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and C-reactive protein(CRP)and adverse reactions was compared.Results The total effective rate in the observation group was 91.38%(53/58),which was significantly higher than that in the control group(75.86%,44/58)(P<0.05).The ACT score in the observation group was(20.61±1.95)points,which was higher than that in the control group[(18.30±1.43)points],and the CAT score was(15.02±2.31)points,lower than that in the control group[(18.41±2.62)points],with statistical significance(P<0.05).The values of FEV1,FEV1/FVC and PEFR in the observation group were(2.20±0.27)L,(61.21±5.28)%and(3.88±0.36)L/s,which were higher than those in the control group[(1.93±0.21)L,(57.33±5.26)%and(3.67±0.41)L/s],with statistical significance(P<0.05).The serum levels of TNF-α,IL-6 and CRP in the observation group were(31.70±5.42)ng/L,(22.05±3.29)ng/L and(9.75±1.60)mg/L,which were lower than t

关 键 词：哮喘-慢性阻塞性肺疾病重叠综合征 中医 肺功能 炎症因子 不良反应 

分 类 号：R256.12[医药卫生—中医内科学]